Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Sana Biotechnology's favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a ...

Plenty of analysts on Wall Street think so. The company boasts an average price target of $93.39 (according to Yahoo! Finance ...

Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Over the past few years, Axsome Therapeutics has made slow and steady clinical and regulatory progress. The company's lineup ...

Investing.com -- IO Biotech Inc (NASDAQ:IOBT) stock plunged 46.5% Wednesday after the clinical-stage biopharmaceutical company announced it would explore strategic alternatives to maximize stockholder ...

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...